The loss of SphK2 activity in hippocampus and temporal GM observed in our study sits in contrast to the findings of Takasugi et al.[59], who reported gain of SphK2 activity in frontal cortex of AD patients. This evidence concerns the gene SPHK2 and Alzheimer disease.